FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

View source ↗

Summary

FDA approves the first gene therapy (Kresladi) for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukocyte Adhesion Deficiency Type

Drugs mentioned

• Kresladi (marnetegragene autotemcel)

Snippet

The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I).